BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33965961)

  • 1. Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival.
    Grobet-Jeandin E; Wirth GJ; Benamran D; Dupont A; Tille JC; Iselin CE
    Urol Int; 2022; 106(2):130-137. PubMed ID: 33965961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.
    Colombo R; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Lucianò R; Conti G; Magnani T; Capogrosso P; Conti A; Pasini L; Burgio G; Guazzoni G; Patriarca C
    Eur Urol Focus; 2018 Jan; 4(1):87-93. PubMed ID: 28753746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
    Kardoust Parizi M; Enikeev D; Glybochko PV; Seebacher V; Janisch F; Fajkovic H; Chłosta PL; Shariat SF
    World J Urol; 2020 Jun; 38(6):1437-1449. PubMed ID: 31493109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
    Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
    Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    Yanagisawa T; Miki J; Yorozu T; Iwatani K; Obayashi K; Sato S; Kimura T; Takahashi H; Egawa S
    J Urol; 2021 Jun; 205(6):1622-1628. PubMed ID: 33502235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.
    Patriarca C; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Guazzoni G; Conti A; Conti G; Lucianò R; Magnani T; Colombo R
    Diagn Pathol; 2016 Jan; 11():6. PubMed ID: 26791567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of tumor invasion to muscularis mucosaevascular plexus on patient outcome in pT1 bladder urothelial carcinoma.
    Sahan A; Gerin F; Garayev A; Bozkurtlar E; Çubuk A; Ozkaptan O; Ertas K; Tanıdır Y; Cam HK; Tınay I
    Arch Ital Urol Androl; 2020 Oct; 92(3):. PubMed ID: 33016055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder.
    Turan T; Efiloğlu Ö; Günaydin B; Özkanli Ş; Nikerel E; Atiş G; Çaşkurlu T; Yildirim A
    Int Braz J Urol; 2018; 44(2):267-272. PubMed ID: 29219283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
    Smits G; Schaafsma E; Kiemeney L; Caris C; Debruyne F; Witjes JA
    Urology; 1998 Dec; 52(6):1009-13; discussion 1013-4. PubMed ID: 9836546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
    Lawless M; Gulati R; Tretiakova M
    Histopathology; 2017 Sep; 71(3):406-414. PubMed ID: 28470753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.